RT Journal Article
SR Electronic
T1 High seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in Perpignan, France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252835
DO 10.1101/2021.03.05.21252835
A1 Beaumont, Adeline
A1 Durand, Cécile
A1 Ledrans, Martine
A1 Schwoebel, Valérie
A1 Noel, Harold
A1 Le Strat, Yann
A1 Diulius, Donatien
A1 Colombain, Léa
A1 Médus, Marie
A1 Gueudet, Philippe
A1 Mouly, Damien
A1 Aumaître, Hugues
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252835.abstract
AB Background In March 2020, many cases of COVID-19 were reported in three socially deprived neighbourhoods of the city of Perpignan, in the south of France, where large sedentary gypsy communities live. A study to measure seroprevalence was conducted in July 2020 to assess the level of contamination in these neighbourhoods after the first wave of the pandemic, and to identify factors associated with seropositivity.Methods SCoPe is a cross-sectional survey conducted in selected persons aged six years old and over living in three neighbourhoods in Perpignan. Households were selected by systematic sampling and participants by random sampling. Collected blood samples were tested for SARS-CoV-2 IgG and IgM antibodies using the EIecsys® immunoassay to target the coronavirus’s spike protein. Antibody seroprevalence was estimated from weighted data and associated factors were investigated using multivariate logistic regression.Results The seroprevalence of anti-SARS-CoV-2 antibodies was 35.4% (95% CI: 30.2-41.0). Over a fifth of seropositive individuals (21.7% ([14.1-31.8]) did not report any COVID-19 symptom. People aged 15-64 years old were at greater risk of seropositivity than those aged 65 years or over. Obesity prevalence was 40.7% (35.8-45.8) and obese people were more likely to be seropositive (aOR=2.0 [1.1-3.8]). The risk of being seropositive was higher in households with clinical COVID-19 cases (One case: aOR=2.5 [1.3-5.0]). In the neighbourhood with the highest measured seroprevalence, people living in a dwelling with 1-2 rooms had a higher risk of being seropositive than those living in a 4-room house (aOR=2.8 [1.2-6.3]). Working during the lockdown was associated with a lower risk of seropositivity (aOR=0.2 [0.03-1.0]).Conclusion Transmission prevalence of the SARS-COV-2 virus in this vulnerable population was very high during the COVID-19 pandemic’s first wave. Our results highlight the need to strengthen and adapt preventive measures by taking into account all social determinants of health, especially housing conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was done by Perpignan Hospital and Santé Publique France (SpF, French Public Health Agency) as part of their missions. Both structures are funded by the French Ministry of Health. This study was also funded by the Occitanie Region. Perpignan Hospital and Santé Publique France are fully responsible for the study protocol, data collection, analysis, interpretation of results, and the writing of this article. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethics approvals by Comité de Protection des Personnes SUD-EST II (ID-RCB:2020-A01828-31, no. 2020-63).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be obtained from a third party and are not publicly available: Anonymised data are available for researchers from the corresponding author, Damien Mouly, on reasonable request.